Comparison of immunogenicity and safety between two paediatric TBE vaccines

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F60162694%3AG44__%2F10%3A00002349" target="_blank" >RIV/60162694:G44__/10:00002349 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Comparison of immunogenicity and safety between two paediatric TBE vaccines

Popis výsledku v původním jazyce

TBE vaccination strategies capable of inducing strong paediatric immunogenicity and acceptable reactogenicity are still under evaluation. This study compared the immunogenicity and safety of the two paediatric TBE vaccines available in Europe (FSME-IMMUN(R) Junior and Encepur (R) Children) following administration of two doses of either vaccine in 303 children aged 1-11 years. Regardless of immunological test or viral antigen used, immunological responses were consistently higher in children vaccinatedwith FSME-IMMUN (R) Junior than those vaccinated with Encepur (R) Children. FSME-IMMUN (R) Junior is also non-inferior to Encepur (R) Children, with respect to NT seropositivity rates (p < 0.0001). Systemic reaction rates were low and similar between the vaccines. However, among children aged 7-11 years, local reactions were significantly higher after the first (p < 0.01) and second (p < 0.001) vaccination with Encepur (R) Children than with FSME-IMMUN (R) Junior, affecting half the chi

Název v anglickém jazyce

Comparison of immunogenicity and safety between two paediatric TBE vaccines

Popis výsledku anglicky

TBE vaccination strategies capable of inducing strong paediatric immunogenicity and acceptable reactogenicity are still under evaluation. This study compared the immunogenicity and safety of the two paediatric TBE vaccines available in Europe (FSME-IMMUN(R) Junior and Encepur (R) Children) following administration of two doses of either vaccine in 303 children aged 1-11 years. Regardless of immunological test or viral antigen used, immunological responses were consistently higher in children vaccinatedwith FSME-IMMUN (R) Junior than those vaccinated with Encepur (R) Children. FSME-IMMUN (R) Junior is also non-inferior to Encepur (R) Children, with respect to NT seropositivity rates (p < 0.0001). Systemic reaction rates were low and similar between the vaccines. However, among children aged 7-11 years, local reactions were significantly higher after the first (p < 0.01) and second (p < 0.001) vaccination with Encepur (R) Children than with FSME-IMMUN (R) Junior, affecting half the chi

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FN - Epidemiologie, infekční nemoci a klinická imunologie

OECD FORD obor

—

Projekt

—

Návaznosti

Z - Vyzkumny zamer (s odkazem do CEZ)

Rok uplatnění

2010

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Vaccine

ISSN

0264-410X

e-ISSN

—

Svazek periodika

28

Číslo periodika v rámci svazku

29

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

6

Strana od-do

—

Kód UT WoS článku

000279863900022

EID výsledku v databázi Scopus

—